Jinhai Medical Technology reports revenue decline, wider loss in 1H 2025

Jinhai Medical Technology Limited reported revenue of S$14.5 million for the six months ended June 30, 2025, a 44.0% decrease from S$25.9 million in the same period last year. This decline was primarily attributed to slower economic growth in Singapore and product mix adjustments for minimally invasive surgical solutions in China. The company recorded a loss for the period of S$10.8 million, widening from S$6.0 million in 1H 2024, with basic and diluted loss per share at S$0.20 compared to S$0.12 previously. Gross profit also fell to S$2.1 million from S$7.4 million, with the gross profit margin dropping from 28.6% to 14.3%.

Administrative expenses decreased to S$12.5 million from S$13.7 million, largely due to a S$1.2 million reduction in equity-settled share-based payments. The group's gearing ratio increased to 52.8% as at June 30, 2025 from 44.3% at Dec. 31, 2024, reflecting higher borrowings and lease liabilities. The company is actively exploring new investment opportunities and aims to expand its business into the Asia Pacific region, particularly China, focusing on minimally invasive surgery solutions.

Post-period, Jinhai Medical Technology announced subscription agreements on July 11, 2025, for 120,000,000 subscription shares at HK$1.35 per share, raising HK$161.0 million for potential mergers and acquisitions, R&D, and general working capital.